AbCellera Biologics Inc. (ABCL) News
Filter ABCL News Items
ABCL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ABCL News Highlights
- ABCL's 30 day story count now stands at 11.
- Over the past 21 days, the trend for ABCL's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- BEAT, DRUG and SITC are the most mentioned tickers in articles about ABCL.
Latest ABCL News From Around the Web
Below are the latest news stories about ABCELLERA BIOLOGICS INC that investors may wish to consider to help them evaluate ABCL as an investment opportunity.
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023VANCOUVER, British Columbia, November 16, 2023--AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023 |
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023VANCOUVER, British Columbia, November 03, 2023--AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023 |
AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2023 Earnings Call TranscriptAbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2023 Earnings Call Transcript November 2, 2023 AbCellera Biologics Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.14. Operator: Good afternoon, and welcome to AbCellera’s Third Quarter 2023 Business Update Conference Call. My name is Kate, and I will facilitate the audio portion of today’s interactive broadcast. [Operator […] |
Q3 2023 Abcellera Biologics Inc Earnings CallQ3 2023 Abcellera Biologics Inc Earnings Call |
Prelude Therapeutics Inc (PRLD) Reports Q3 Financial Results and Strategic Pipeline ProgressCompany prioritizes SMARCA2 degrader and CDK9 inhibitor programs, reports cash runway into 2026 |
AbCellera Biologics (ABCL) Q3 2023 Earnings Call TranscriptImage source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL)Q3 2023 Earnings CallNov 02, 2023, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon, and welcome to AbCellera's third quarter 2023 business update conference call. |
AbCellera Biologics Inc (ABCL) Reports Q3 2023 Earnings: Revenue Drops to $7 MillionCompany's Net Loss Widens to $0.10 Per Share |
AbCellera Reports Q3 2023 Business ResultsVANCOUVER, British Columbia, November 02, 2023--AbCellera Reports Q3 2023 Business Results |
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyWILMINGTON, Del. & VANCOUVER, British Columbia, November 01, 2023--Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology |
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023VANCOUVER, British Columbia, October 31, 2023--AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023 |